Analysts expect Husky Energy Inc. (TSE:HSE) to report $0.07 EPS on February, 23.They anticipate $0.08 EPS change or 800.00% from last quarter’s $-0.01 EPS. T_HSE’s profit would be $70.36M giving it 58.89 P/E if the $0.07 EPS is correct. After having $0.14 EPS previously, Husky Energy Inc.’s analysts see -50.00% EPS growth. The stock increased 0.67% or $0.11 during the last trading session, reaching $16.49. About 872,562 shares traded. Husky Energy Inc. (TSE:HSE) has 0.00% since February 17, 2017 and is . It has underperformed by 16.70% the S&P500.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $992.85 million. The companyÂ’s lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.
Husky Energy Inc., together with its subsidiaries, operates as an integrated energy company. The company has market cap of $16.57 billion. It operates through two divisions, Upstream and Downstream. It has a 63.18 P/E ratio. The Upstream segment engages in the exploration for, and development and production of crude oil, bitumen, natural gas, and natural gas liquids; marketing of the company's and other producers' crude oil, natural gas, natural gas liquids, sulphur, and petroleum coke; pipeline transportation and blending of natural gas and crude oil; and storage of crude oil, diluent, and natural gas.
Among 10 analysts covering Husky Energy Inc. (TSE:HSE), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Husky Energy Inc. had 45 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was upgraded by Desjardins Securities to “Buy” on Tuesday, June 28. The rating was upgraded by FirstEnergy Capital on Thursday, November 5 to “Outperform”. As per Monday, January 23, the company rating was upgraded by Goldman Sachs. The stock has “” rating by Raymond James on Monday, June 6. On Thursday, December 1 the stock rating was upgraded by Desjardins Securities to “Top Pick”. The rating was maintained by Raymond James on Friday, February 24 with “Market Perform”. On Monday, November 2 the stock rating was upgraded by BMO Capital Markets to “Outperform”. The rating was maintained by RBC Capital Markets with “Sector Perform” on Wednesday, May 31. The stock of Husky Energy Inc. (TSE:HSE) earned “Outperform” rating by RBC Capital Markets on Wednesday, December 9. BMO Capital Markets maintained Husky Energy Inc. (TSE:HSE) on Tuesday, December 5 with “Market Perform” rating.
Since January 1, 0001, it had 0 insider buys, and 4 sales for $61,523 activity.
The stock decreased 2.37% or $0.58 during the last trading session, reaching $23.93. About 581,392 shares traded. PTC Therapeutics, Inc. (PTCT) has risen 104.51% since February 17, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.
Consonance Capital Management Lp holds 8.73% of its portfolio in PTC Therapeutics, Inc. for 3.95 million shares. Great Point Partners Llc owns 1.10 million shares or 4.28% of their US portfolio. Moreover, Spark Investment Management Llc has 0.77% invested in the company for 717,000 shares. The Massachusetts-based Bogle Investment Management L P De has invested 0.76% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 170,535 shares.
Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on March, 15. They expect $-0.23 earnings per share, up 70.51% or $0.55 from last year’s $-0.78 per share. After $-0.67 actual earnings per share reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -65.67% EPS growth.